An interventional study of CART-19 and 20 cells and Cyclophosphamide in Non-hodgkin Lymphoma,B Cell, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-07.
Sponsored by Henan Cancer Hospital · Not applicable, Interventional, and Treatment
This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 20 is below the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Henan Cancer Hospital is the lead sponsor of 228 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of double-target CART-19 and 20 cells. The double-target CART-19 and 20 cells are to be administered on day0.
Biological: CART-19 and 20 cells · Drug: Cyclophosphamide · Drug: Fludarabine
Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
safety as assessed by the occurrence of study related adverse events
monitor the occurrence of study related adverse events
Time frame: from the date of recieving intravenous CART cells up to one month
objective response rate
the proportion of patients benefit from the therapy
Time frame: 28 days and 3 months after recieving intravenous CART cells
peripheral blood CART cell copy number
The highest concentration of CART cells in peripheral blood, the time to reach the highest concentration, and the area under the curve at 28 days after recieving intravenous CART cells
Time frame: from the date of recieving intravenous CART cells up to one month
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Cancer Hospital